TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive In Brief: ACS Awards Three More Grants For Prevention Research; AHF Establishes Chair In Nutrition November 14, 1980
TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
